The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1591
ISSUE1591
February 10, 2020
Brolucizumab (Beovu) for Age-Related Macular Degeneration
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Brolucizumab (Beovu) for Age-Related Macular Degeneration
February 10, 2020 (Issue: 1591)
Brolucizumab-dbll (Beovu — Novartis), a vascular
endothelial growth factor (VEGF) inhibitor, has been
approved by the FDA as an intravitreal injection for
treatment of neovascular (wet) age-related macular
degeneration (AMD). It is the fourth...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.